Metabolic syndrome and skin: Psoriasis and beyond

Indian Journal of Dermatology

Volumn 58, Issue 4, 2013, Pages 299-305

  Padhi, Tanmay ^a   Garima, ^a  

^a VSS Medical College & Hospital   (India)

Author keywords

Androgenetic alopecia; Cardiovascular risk; Chronic inflammation; Metabolic syndrome; Psoriasis

Indexed keywords

ADIPONECTIN; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; AMINE OXIDASE (FLAVIN CONTAINING); CATECHOL METHYLTRANSFERASE; CHOLESTEROL; CYTOCHROME P450; GLUCOSE; GLUTATHIONE TRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNSPECIFIC MONOOXYGENASE; VASCULAR CELL ADHESION MOLECULE 1;

ACANTHOSIS NIGRICANS; ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CHILDHOOD OBESITY; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; DEPRESSION; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOCRINE DISEASE; EXERCISE; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; HEREDITY; HUMAN; HYPERALDOSTERONISM; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOADIPONECTINEMIA; HYPOCHOLESTEROLEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LICHEN PLANUS; LIFESTYLE MODIFICATION; MALE TYPE ALOPECIA; MELANOMA; METABOLIC SYNDROME X; NON MELANOMA SKIN CANCER; NONHUMAN; OVERNUTRITION; OXIDATIVE STRESS; PSORIASIS; RISK FACTOR; SEDENTARY LIFESTYLE; SKIN CANCER; SKIN DISEASE; SKIN TAG; SMOKING; SOCIAL STATUS; SUPPURATIVE HIDRADENITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; URBANIZATION;

EID: 84880264254     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.113950     Document Type: Article

References (98)

1. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066-72.
2. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
3. Third report of the National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143-421.
4. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol 2007;157:68-73.
5. Wong ND. Metabolic syndrome: Cardiovascular risk assessment and management. Am J Cardiovasc Drugs 2007;7:259-72.
6. Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: The Chennai urban rural epidemiology Study (CURES-34). Diabetes Metab Res Rev 2007;23:127-34.
7. Davidovici BB, Sattar N, Prinz JC, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010;130:1785-96.
8. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93:S64-73.
9. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52:262-7.
10. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suarez-Farinas M, Fuentes-Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-94.
11. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci 2009;84:705-12.
12. Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: A unifying hypothesis. J Nutr Biochem 2008;19:491-504.
13. Mena S, Ortega A, Estrela JM. Oxidative stress in environmentalinduced carcinogenesis. Mutat Res 2009;674:36-44.
14. Moeller H. On metabolism of noradrenaline in the skin: Activity of catechol-O-methyl transferase and monoamine oxidase. Acta Derm Venereol 1963;43:552-5.
15. Zech LA, Gross EG, Peck GL, Brewer HB. Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin. A prospective study. Arch Dermatol 1983;119:987-93.
16. Bershad S, Rubinstein A, Paterniti JR, Le NA, Poliak SC, Heller B, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985;313:981-5.
17. Rodondi N, Darioli R, Ramelet AA, Hohl D, Lenain V, Perdrix J, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: A pharmacogenetic study. Ann Intern Med 2002;136:582-9.
18. Kamezaki F, Sonoda S, Tomotsune Y, Yunaka H, Otsuji Y. Seasonal variation in metabolic syndrome prevalence. Hypertens Res 2010;33:568-72.
19. Woodhouse PR, Khaw KT, Plummer M. Seasonal variation of serum lipids in an elderly population. Age Ageing 1993;22:273-8.
20. Thorp AA, Owen N, Neuhaus M, Dunstan DW. Sedentary behaviors and subsequent health outcomes in adults; A systematic review of longitudinal studies, 1996-2011. Am J Prev Med 2011;41:207-15.
21. Hulthe J, Hultén LM, Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: Atherosclerosis and insulin resistance study. Metabolism 2003;52:1612-4.
22. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-9.
23. Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, Balkau B, et al. Correlation of the leptin: Adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia 2009;52:2345-9.
24. Auwerx J, Staels B. Leptin. Lancet 1998;351:737-42.
25. Matilainen V, Koskela P, Keinanen-Kiukaanniemi S. Early androgenetic alopecia as a marker of insulin resistance. Lancet 2000;356:1165-6.
26. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9:136-9.
27. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58:1031-42.
28. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: Results from an Italian case-control study. J Invest Dermatol 2005;125:61-7.
29. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007;167:1670-5.
30. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994;102:145-9.
31. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23.
32. Gomi T, Shiohara T, Munakata T, Imanishi K, Nagashima M. Interleukin 1 alpha, tumor necrosis factor alpha, and interferon gamma in psoriasis. Arch Dermatol 1991;127:827-30.
33. Cabrijan L, Batinac T, Lenkovic M, Gruber F. The distinction between lesional and non-lesional skin in psoriasis vulgaris through expression of adhesion molecules ICAM-1 and VCAM-1. Med Hypotheses 2009;72:327-9.
34. Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008;159:1207-8.
35. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008;19:5-21.
36. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113:1664-75.
37. Elias PM, Arbiser J, Brown BE, Rossiter H, Man MQ, Cerimele F, et al. Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: Implications for the pathogenesis of psoriasis. Am J Pathol 2008;173:689-99.
38. Kaplan MJ. Cardiometabolic risk in psoriasis: Differential effects of biologic agents. Vasc Health Risk Manag 2008;4:1229-35.
39. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978;99:469-75.
40. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298-304.
41. Naldi L, Parazzini F, Brevi A, Peserico A, Veller Fornasa C, Grosso G, et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol 1992;127:212-7.
42. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-6.
43. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-8.
44. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008;216:152-5.
45. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol 2007;157:68-73.
46. Zindanci I, Albayrak O, Kavala M, Kocaturk E, Can B, Sudogan S, et al. Prevalence of metabolic syndrome in patients with psoriasis. Sceintifc World Journal [Internet] 2012 Apr[cited 2012 Aug10];2012:312463 Available from: http://www.hindawi. com/journals/tswj/2012/312463/.
47. Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol 2010;76:662-5.
48. Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006;155:1165-9.
49. Mebazaa A, El Asmi M, Zidi W, Zayani Y, Cheikh Rouhou R, El Ounifi S, et al. Metabolic syndrome in Tunisian psoriatic patients: Prevalence and determinants. J Eur Acad Dermatol Venereol 2011;25:705-9.
50. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010;162:633-6.
51. Au SC, Goldminz AM, Loo DS, Dumont N, Levine D, Volf E, et al. Association between pediatric psoriasis and the metabolic syndrome. J Am Acad Dermatol 2012;66:1012-3.
52. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52:262-7.
53. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004;51:447-50.
54. Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, Ihlemann N, Baunbjerg Nielsen D, et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005;42:517-25.
55. Farshchian M, Zamanian A, Farshchian M, Monsef AR, Mahjub H. Serum lipid level in Iranian patients with psoriasis. J Eur Acad Dermatol Venereol 2007;21:802-5.
56. Kim GW, Park HJ, Kim HS, Kim SH, Ko HC, Kim BS, et al. Analysis of cardiovascular risk factors and metabolic syndrome in Korean patients with psoriasis. Ann Dermatol 2012;24:11-5.
57. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: Results of a large population-based Dutch cohort. J Invest Dermatol 2010;130:962-7.
58. Hoffmann R, Happle R. Current understanding of androgenetic alopecia. Part I: Etiopathogenesis. Eur J Dermatol 2000;10:319-27.
59. Rebora A. Pathogenesis of androgenetic alopecia. J Am Acad Dermatol 2004;50:777-9.
60. Nabaie L, Kavand S, Robati RM, Sarrafi-Rad N, Kavand S, Shahgholi L, et al. Androgenic alopecia and insulin resistance: Are they really related? Clin Exp Dermatol 2009;34:694-7.
61. Severi G, Sinclair R, Hopper JL, English DR, McCredie MR, Boyle P, et al. Androgenetic alopecia in men aged 40-69 years: Prevalence and risk factors. Br J Dermatol 2003;149:1207-13.
62. Arias-Santiago S, Gutierrez-Salmeron MT, Castellote-Caballero L, Buendía-Eisman A, Naranjo-Sintes R. Androgenetic alopecia and cardiovascular risk factors in men and women: A comparative study. J Am Acad Dermatol 2010;63:420-9.
63. Ahouansou S, Le Toumelin P, Crickx B, Descamps V. Association of androgenetic alopecia and hypertension. Eur J Dermatol 2007;17:220-2.
64. Hirsso P, Rajala U, Hiltunen L, Jokelainen J, Keinänen-Kiukaanniemi S, Näyhä S. Obesity and low-grade inflammation among young Finnish men with early-onset alopecia. Dermatology 2007;214:125-9.
65. Su LH, Chen TH. Association of androgenetic alopecia with metabolic syndrome in men: A community-based survey. Br J Dermatol 2010;163:371-7.
66. Yi SM, Son SW, Lee KG, Kim SH, Lee SK, Cho ER, et al. Gender-specific association of androgenetic alopecia with metabolic syndrome in a middle-aged Korean population. Br J Dermatol 2012;167:306-13.
67. Hirsso P, Laakso M, Matilainen V, Hiltunen L, Rajala U, Jokelainen J, et al. Association of insulin resistance linked diseases and hair loss in elderly men. Finnish population-based study. Cent Eur J Public Health 2006;14:78-81.
68. Arias-Santiago S, Gutierrez-Salmeron MT, Castellote-Caballero L, Buendia-Eisman A, Naranjo-Sintes R. Androgenetic alopecia and cardiovascular risk factors in men and women: A comparative study. J Am Acad Dermatol 2010;63:420-9.
69. Arias-Santiago S, Gutierrez-Salmeron MT, Castellote-Caballero L, Buendia-Eisman A, Naranjo-Sintes R. Male androgenetic alopecia and cardiovascular risk factors: A case-control study. Actas Dermosifiliogr 2010;101:248-56.
70. Lotufo PA, Chae CU, Ajani UA, Hennekens CH, Manson JE. Male pattern baldness and coronary heart disease: The Physicians' Health Study. Arch Intern Med 2000;160:165-71.
71. Kong AS, Williams RL, Smith M, Sussman AL, Skipper B, Hsi AC, et al. Acanthosis nigricans and diabetes risk factors: Prevalence in young persons seen in southwestern US primary care practices. Ann Fam Med 2007;5:202-8.
72. Burke JP, Hale DE, Hazuda HP, Stern MP. A quantitative scale of acanthosis nigricans. Diabetes Care 1999;22:1655-9.
73. Stuart CA, Smith MM, Gilkison CR, Shaheb S, Stahn RM. Acanthosis Nigricans among native Americans: An indicator of high diabetes risk. Am J Public Health 1994;84:1839-42.
74. Gilkison C, Stuart CA. Assessment of patients with acanthosis nigricans skin lesion for hyperinsulinemia, insulin resistance and diabetes risk. Nurse Pract 1992;17:26-44.
75. Rendon MI, Cruz PD Jr, Sontheimer RD, Bergstresser PR. Acanthosis nigricans: A cutaneous marker of tissue resistance to insulin. J Am Acad Dermatol 1989;21:461-9.
76. Dassanayake AS, Kasturiratne A, Niriella MA, Kalubovila U, Rajindrajith S, de Silva AP, et al. Prevalence of acanthosis Nigricans in an urban population in Sri Lanka and its utility to detect metabolic syndrome. BMC Res Notes [Internet]. 2011 Jan [cited 2012 Aug 10];425 Available from: http://www. ncbi.nlm.nih.gov/pmc/articles/PMC3041677.
77. Ice CL, Murphy E, Minor VE, Neal WA. Metabolic syndrome in fifth grade children with acanthosis nigricans: Results from the CARDIAC project. World J Pediatr 2009;5:23-30.
78. Jones LH, Ficca M. Is Acanthosis Nigricans a reliable indicator for risk of type 2 diabetes? J Sch Nurs 2007;23:247-51.
79. El Safoury O, Fawzi M, Abdel Hay RM, Hassan AS, El Maadawi Z, Rashed L. Increased tissue leptin hormone level and mast cell count in skin tags: A possible role of adipoimmune in the growth of benign skin growths. Indian J Dermatol Venereol Leprol 2010;76:538-42.
80. Sudy E, Urbina F, Maliqueo M, Sir T. Screening of glucose/ insulin metabolic alterations in men with multiple skin tags on the neck. J Dtsch Dermatol Ges 2008;6:852-5, 852-6.
81. Gorpelioglu C, Erdal E, Ardicoglu Y, Adam B, Sarifakioglu E. Serum leptin, atherogenic lipids and glucose levels in patients with skin tags. Indian J Dermatol 2009;54:20-2.
82. El Safoury OS, Abdel Hay RM, Fawzy MM, Kadry D, Amin IM, Abu Zeid OM, et al. Skin tags, leptin, metabolic syndrome and change of the life style. Indian J Dermatol Venereol Leprol 2011;77:577-80.
83. Jowkar F, Fallahi A, Namazi MR. Is there any relation between serum insulin and insulin-like growth factor-I in non-diabetic patients with skin tag? J Eur Acad Dermatol Venereol 2010;24:73-4.
84. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996;35:191-4.
85. Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies. J Am Acad Dermatol 2008;59:596-601.
86. Sabat R, Chanwangpong A, Schneider-Burrus S, Metternich D, Kokolakis G, Kurek A, et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One [Internet].2012 Feb [cited 2012 Aug10];7(2) Available from: http:// http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone. 0031810
87. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
88. Stattin P, Björ O, Ferrari P, Lukanova A, Lenner P, Lindahl B, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007;30:561-7.
89. Nagel G, Bjoørge T, Stocks T, Manjer J, Hallmans G, Edlinger M, et al. Metabolic risk factors and skin cancer in the metabolic syndrome and cancer project (Me-Can). Br J Dermatol 2012;167:59-67.
90. Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K. Cancer risk among patients hospitalized for Type 1 diabetes mellitus: A population-based cohort study in Sweden. Diabet Med 2010;27:791-7.
91. Rosengren A, Himmelmann A, Wilhelmsen L, Branehög I, Wedel H. Hypertension and long-term cancer incidence and mortality among Swedish men. J Hypertens 1998;16:933-40.
92. Dreiher J, Shapiro J, Cohen AD. Lichen planus and dyslipidaemia: A case-control study. Br J Dermatol 2009;161:626-9.
93. Arias-Santiago S, Buendia-Eisman A, Aneiros-Fernandez J, Giron-Prieto MS, Gutierrez-Salmeron MT, Mellado VG, et al. Cardiovascular risk factors in patients with lichen planus. Am J Med 2011;124:543-8.
94. Powell SM, Ellis JP, Ryan TJ, Vickers HR. Glucose tolerance in lichen planus. Br J Dermatol 1974;91:73-5.
95. Romero MA, Seoane J, Varela-Centelles P, Diz-Dios P, Garcia-Pola MJ. Prevalence of diabetes mellitus amongst oral lichen planus patients. Clinical and pathological characteristics. Med Oral 2002;7:121-9.
96. Nascimento IS, Quaio CR, Sinicato NA, Appenzeller S, de Carvalho JF. Aspects of atherosclerosis and metabolic syndrome in lupus erythematosus. Acta Reumatol Port 2010;35:294-300.
97. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:338-46.
98. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.